Vir Biotechnology Inc.’s recently made public that its Director SATO VICKI L unloaded Company’s shares for reported $0.44 million on Jun 30. In the deal valued at $24.66 per share,18,000 shares were sold. As a result of this transaction, SATO VICKI L now holds 1,315,351 shares worth roughly $ 16.95 million.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Then, SVF Endurance (Cayman) Ltd sold 700 shares, generating $17,577 in total proceeds. Upon selling the shares at $25.11, the 10% Owner now owns 16,684,041 shares.
Before that, SVF Endurance (Cayman) Ltd sold 89,942 shares. Vir Biotechnology Inc. shares valued at $2,264,731 were divested by the 10% Owner at a price of $25.18 per share. As a result of the transaction, SVF Endurance (Cayman) Ltd now holds 16,684,741 shares, worth roughly $215.07 million.
JP Morgan upgraded its Vir Biotechnology Inc. [VIR] rating to an Overweight from a a Neutral in a research note published on Friday, March 06, 2023; the price target was decreased to $34 from $35. PT values the company’s stock at a premium of 62.09 to its Friday closing price.
Price Performance Review of VIR
On Friday, Vir Biotechnology Inc. [NASDAQ:VIR] saw its stock jump 0.31% to $12.89. On the same session, the stock had its day’s lowest price of $12.57, but rose to a high of $12.98. Over the last five days, the stock has gained 4.97%. Vir Biotechnology Inc. shares have fallen nearly -49.07% since the year began. Nevertheless, the stocks have fallen -48.77% over the past one year. While a 52-week high of $31.55 was reached on 01/27/23, a 52-week low of $12.14 was recorded on 08/21/23. SMA at 50 days reached $18.32, while 200 days put it at $23.81. A total of 0.78 million shares were traded, compared to the trading of 1.15 million shares in the previous session.
Levels Of Support And Resistance For VIR Stock
The 24-hour chart illustrates a support level at 12.65, which if violated will result in even more drops to 12.40. On the upside, there is a resistance level at 13.06. A further resistance level may holdings at 13.22. The Relative Strength Index (RSI) on the 14-day chart is 30.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.06%. Stochastics %K at 41.50% indicates the stock is a holding.
How much short interest is there in Vir Biotechnology Inc.?
A steep rise in short interest was recorded in Vir Biotechnology Inc. stocks on Aug 14, 2023, growing by 1.06 million shares to a total of 5.03 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 3.97 million shares. There was a rise of 21.07%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.33% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.65.
Vir Biotechnology Inc. [VIR] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 12,533,053 shares, or roughly 9.36% of the outstanding VIR shares. In other words, the investor’s shares have risen by 204,415 from its previous 13-F filing of 12328638.0. Additionally, The Vanguard Group, Inc. decreased -0.44% of its stake after which the total value it holdings stand at $142,132,954, while SSgA Funds Management, Inc. added 0.64% of its stake to hold $76.3 million in the firm. Over the last quarter, Temasek Holdings Pte Ltd. sold -681,362 shares of Vir Biotechnology Inc., while Baillie Gifford & Co. sold -2,581 shares. At present, AllianceBernstein LP is holding 2,751,716 shares valued at $38.74 million. Perceptive Advisors LLC owned 1,958,264 shares of the company at the time of its most recent 13F filing, worth $27.57 million.
According to FactSet, Vir Biotechnology Inc.’s share price will average $33.88 in the next year, based on opinions of analysts polled by the firm. This is up nearly 82.88 percent from its previous closing price of $12.85. Analysts expect Vir Biotechnology Inc. stock to reach the higher price of $95.00, while the lowest price estimate is $15.00. However, 9 analysts have rated VIR stock as a Buy in their predictions for 2023.